SRDX Stock Recent News
SRDX LATEST HEADLINES
SurModics (SRDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.50 per share a year ago.
Surmodics (SRDX) new addition to its Pounce Thrombectomy Platform is recommended for use in vessels with a diameter between 2 mm and 4 mm for clot removal.
SurModics (SRDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust segmental revenues.
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Investors are optimistic about Surmodics' (SRDX) consistent efforts to boost R&D.
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Needham--SRDX, a provider of medical device and in vitro diagnostic technologies, announced management will participate in upcoming investor conferences.
Surmodics, Inc. (NASDAQ:SRDX ) Q3 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Gary Maharaj - President & Chief Executive Officer Timothy Arens - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Michael Matson - Needham & Company Michael Petusky - Barrington Research James Sidoti - Sidoti & Company Operator Welcome everyone to Surmodics Third Quarter of Fiscal Year 2023 Earnings Call. Please note that this call is being webcast.